Lunai Bioworks Inc. (LNAI)
NASDAQ: LNAI · Real-Time Price · USD
0.273
-0.089 (-24.48%)
Mar 6, 2026, 10:10 AM EST - Market open
Lunai Bioworks Employees
Lunai Bioworks had 29 employees as of June 30, 2025. The number of employees increased by 4 or 16.00% compared to the previous year.
Employees
29
Change (1Y)
4
Growth (1Y)
16.00%
Revenue / Employee
n/a
Profits / Employee
-$4,328,395
Market Cap
6.60M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 57 |
| Bolt Biotherapeutics | 40 |
| KALA BIO | 38 |
| NuCana | 22 |
| BiomX | 20 |
| SeaStar Medical Holding | 19 |
| CalciMedica | 15 |
| Cardio Diagnostics Holdings | 15 |
LNAI News
- 15 days ago - Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping - PRNewsWire
- 21 days ago - Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC - PRNewsWire
- 25 days ago - Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data - PRNewsWire
- 5 weeks ago - Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons - PRNewsWire
- 5 weeks ago - Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery - PRNewsWire
- 2 months ago - Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance - PRNewsWire
- 3 months ago - Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market - PRNewsWire
- 3 months ago - Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models - PRNewsWire